- Latest available (Revised)
- Original (As adopted by EU)
When the UK left the EU, legislation.gov.uk published EU legislation that had been published by the EU up to IP completion day (31 December 2020 11.00 p.m.). On legislation.gov.uk, these items of legislation are kept up-to-date with any amendments made by the UK since then.
Legislation.gov.uk publishes the UK version. EUR-Lex publishes the EU version. The EU Exit Web Archive holds a snapshot of EUR-Lex’s version from IP completion day (31 December 2020 11.00 p.m.).
Commission Implementing Decision of 8 August 2012 amending Decision 2002/253/EC laying down case definitions for reporting communicable diseases to the Community network under Decision No 2119/98/EC of the European Parliament and of the Council (notified under document C(2012) 5538) (Text with EEA relevance) (2012/506/EU), Division 2. is up to date with all changes known to be in force on or before 09 August 2024. There are changes that may be brought into force at a future date. Changes that have been made appear in the content and are referenced with annotations.
Revised legislation carried on this site may not be fully up to date. Changes and effects are recorded by our editorial team in lists which can be found in the ‘Changes to Legislation’ area. Where those effects have yet to be applied to the text of the legislation by the editorial team they are also listed alongside the legislation in the affected provisions. Use the ‘more’ link to open the changes and effects relevant to the provision you are viewing.
Any person who has any of the clinical conditions as defined in the European AIDS case definition for:
Adults and adolescents ≥ 15 years
Children < 15 years of age
Adults, adolescents and children aged ≥ 18 months
At least one of the following three:
Positive result of a HIV screening antibody test or a combined screening test (HIV antibody and HIV p24 antigen) confirmed by a more specific antibody test (e.g. Western blot)
Positive result of 2 EIA antibody test confirmed by a positive result of a further EIA test
Positive results on two separate specimens from at least one of the following three:
Detection of HIV nucleic acid (HIV-RNA, HIV-DNA)
Demonstration of HIV by HIV p24 antigen test, including neutralisation assay
Isolation of HIV
Children aged < 18 months
Positive results on two separate specimens (excluding cord blood) from at least one of the following three:
Isolation of HIV
Detection of HIV nucleic acid (HIV-RNA, HIV-DNA)
Demonstration of HIV by HIV p24 antigen test, including neutralisation assay in a child ≥ 1 month of age
HIV infection
Any person meeting the laboratory criteria for HIV infection
AIDS
Any person meeting the clinical criteria for AIDS and the laboratory criteria for HIV infection
Any person with at least one of the following clinical forms:
At least one the following two:
Papular or vesicular lesion
Depressed black eschar with surrounding oedema
Fever or feverishness
AND at least one of the following two:
Severe abdominal pain
Diarrhoea
Fever or feverishness
AND at least one of the following two:
Acute respiratory distress
Radiological evidence of mediastinal widening
Fever
AND at least one of the following three:
Convulsions
Loss of consciousness
Meningeal signs
Isolation of Bacillus anthracis from a clinical specimen
Detection of Bacillus anthracis nucleic acid in a clinical specimen
Positive nasal swab without clinical symptoms does not contribute to a confirmed diagnosis of a case
At least one of the following three epidemiological links:
Animal to human transmission
Exposure to a common source
Exposure to contaminated food/drinking water
Any person meeting the clinical criteria and with an epidemiological link
Any person meeting the clinical and the laboratory criteria
Any person with one of the following two:
Fever AND signs and symptoms of acute respiratory infection
Death from an unexplained acute respiratory illness
At least one of the following three:
Isolation of influenza A/H5N1 from a clinical specimen
Detection of influenza A/H5 nucleic acid in a clinical specimen
Influenza A/H5 specific antibody response (four-fold or greater rise or single high titre)
At least one of the following four:
Human to human transmission by having been in close contact (within 1 metre) to a person reported as probable or confirmed case
Laboratory exposure: where there is a potential exposure to influenza A/H5N1
Close contact (within 1 metre) with an animal with confirmed A/H5N1 infection other than poultry or wild birds (e.g. cat or pig)
Reside in or have visited an area where influenza A/H5N1 is currently suspected or confirmed(1) AND at least one of the following two:
Having been in close contact (within 1 metre) with sick or dead domestic poultry or wild birds(2) in the affected area
Having been in a home or a farm where sick or dead domestic poultry have been reported in the previous month in the affected area
Any person meeting the clinical and the epidemiological criteria
Any person with a positive test for influenza A/H5 or A/H5N1 performed by a laboratory which is not a National Reference Laboratory participating in the EU Community Network of Reference Laboratories for human influenza (CNRL)
Any person with a positive test for influenza A/H5 or A/H5N1 performed by a National Reference Laboratory participating in the EU Community Network of Reference Laboratories for human influenza (CNRL)
Any person with a laboratory confirmation by a WHO Collaborating Centre for H5
Any person with at least one of the following clinical forms:
At least one of the following two:
Bilateral cranial nerve impairment (e.g. diplopia, blurred vision, dysphagia, bulbar weakness)
Peripheral symmetric paralysis
Any infant with at least one of the following six:
Constipation
Lethargy
Poor feeding
Ptosis
Dysphagia
General muscle weakness
The type of botulism usually encountered in infants (< 12 months of age) can affect children also over 12 months of age and occasionally adults, with altered gastrointestinal anatomy and microflora
At least one of the following two:
Isolation of Clostridium botulinum for infant botulism (stool) or wound botulism (wound) (isolation of Clostridium botulinum in stool of adults not relevant for the diagnosis of food-borne botulism)
Detection of botulinum toxin in a clinical specimen
At least one of the following two epidemiological links:
Exposure to a common source (e.g. food, sharing of needles or other devices)
Exposure to contaminated food/drinking water
Any person meeting the clinical criteria and with an epidemiological link
Any person meeting the clinical and the laboratory criteria
Any person with Fever
And at least one of following seven:
Sweating (profuse, malodorous, specially nocturnal)
Chills
Arthralgia
Weakness
Depression
Headache
Anorexia
At least one of the following two:
Isolation of Brucella spp. from a clinical specimen
Brucella specific antibody response (Standard Agglutination Test, Complement Fixation, ELISA)
At least one of the following four epidemiological links:
Exposure to contaminated food/drinking water
Exposure to products from a contaminated animal (milk or milk products)
Animal to human transmission (contaminated secretions or organs e.g. vaginal discharge, placenta)
Exposure to a common source
Any person meeting the clinical criteria and with an epidemiological link
Any person meeting the clinical and the laboratory criteria
Any person with at least one of the following three:
Diarrhoea
Abdominal pain
Fever
Isolation of Campylobacter spp. from stool or blood
Differentiation of Campylobacter spp. should be performed if possible
At least one of the following five epidemiological links:
Animal to human transmission
Human to human transmission
Exposure to a common source
Exposure to contaminated food/drinking water
Environmental exposure
Any person meeting the clinical criteria and with an epidemiological link
Any person meeting the clinical and the laboratory criteria
Any person with at least one of the following clinical forms:
At least one of the following six:
Urethritis
Epididymitis
Acute salpingitis
Acute endometritis
Cervicitis
Proctitis
In newborn children at least one of the following two:
Conjunctivitis
Pneumonia
At least one of the following five:
Urethritis
Genital ulcer
Inguinal lymphadenopathy
Cervicitis
Proctitis
At least one of the following three:
Isolation of Chlamydia trachomatis from a specimen of the ano-genital tract or from the conjunctiva
Demonstration of Chlamydia trachomatis by DFA test in a clinical specimen
Detection of Chlamydia trachomatis nucleic acid in a clinical specimen
At least one of the following two:
Isolation of Chlamydia trachomatis from a specimen of the ano-genital tract or from the conjunctiva
Detection of Chlamydia trachomatis nucleic acid in a clinical specimen
AND
Identification of serovar (genovar) L1, L2 or L3
An epidemiological link by human to human transmission (sexual contact or vertical transmission)
Any person meeting the clinical criteria and with an epidemiological link
Any person meeting the laboratory criteria
Any person with at least one of the following two:
Diarrhoea
Vomiting
Isolation of Vibrio cholerae from a clinical specimen
AND
Demonstration of O1 or O139 antigen in the isolate
AND
Demonstration of cholera-enterotoxin or the cholera-enterotoxin gene in the isolate
At least one of the following four epidemiological links:
Exposure to a common source
Human to human transmission
Exposure to contaminated food/drinking water
Environmental exposure
Any person meeting the clinical criteria and with an epidemiological link
Any person meeting the clinical and the laboratory criteria
Any person with a progressive neuropsychiatric disorder with a duration of illness of at least six months
Routine investigations do not suggest an alternative diagnosis
No history of exposure to human pituitary hormones or human dura mater graft
No evidence of a genetic form of transmissible spongiform encephalopathy
Any person with at least four of the following five:
Early psychiatric symptoms(3)
Persistent painful sensory symptoms(4)
Ataxia
Myoclonus or chorea or dystonia
Dementia
Neuropathological confirmation: spongiform change and extensive prion protein deposition with florid plaques throughout the cerebrum and cerebellum
EEG does not show the typical appearance(5) of sporadic CJD(6) in the early stages of the illness
Bilateral pulvinar high signal on MRI brain scan
A positive tonsil biopsy(7)
An epidemiological link by human to human transmission (e.g. blood transfusion)
Any person fulfilling the preconditions
AND
meeting the clinical criteria
AND
a negative EEG for sporadic CJD(8)
Any person fulfilling the preconditions
AND
meeting the clinical criteria
AND
a negative EEG for sporadic CJD(9)
AND
a positive MRI brain scan
OR
Any person fulfilling the preconditions
AND
a positive tonsil biopsy
Any person fulfilling the preconditions
AND
meeting the diagnostic criteria for case confirmation
Any person with at least one of the following two:
Diarrhoea
Abdominal pain
At least one of the following four:
Demonstration of Cryptosporidium oocysts in stool
Demonstration of Cryptosporidium in intestinal fluid or small-bowel biopsy specimens
Detection of Cryptosporidium nucleic acid in stool
Detection of Cryptosporidium antigen in stool
One of the following five epidemiological links:
Human to human transmission
Exposure to a common source
Animal to human transmission
Exposure to contaminated food/drinking water
Environmental exposure
Any person meeting the clinical criteria and with an epidemiological link
Any person meeting the clinical and the laboratory criteria
Any person with at least one of the following clinical forms:
An upper respiratory tract illness with laryngitis or nasopharyngitis or tonsillitis
AND
an adherent membrane/pseudomembrane
An upper respiratory tract illness with laryngitis or nasopharyngitis or tonsillitis
WITHOUT
an adherent membrane/pseudomembrane.
Skin lesion
Lesion of conjunctiva or mucous membranes
Isolation of toxin-producing Corynebacterium diphtheriae, Corynebacterium ulcerans or Corynebacterium pseudotuberculosis from a clinical specimen.
At least one of the following epidemiological links:
Human to human transmission
Animal to human transmission
Any person meeting the clinical criteria for classical respiratory diphtheria
Any person meeting the clinical criteria for diphtheria (Classic Respiratory Diphtheria, Mild Respiratory Diphtheria, Cutaneous Diphtheria, Diphtheria of other sites) with an epidemiological link to a human confirmed case or with an epidemiological link to animal to human transmission
Any person meeting the laboratory criteria AND at least one of the clinical forms
Not relevant for surveillance purposes
At least one of the following five:
Histopathology or parasitology compatible with Echinococcus multilocularis or granulosus (e.g. direct visualisation of the protoscolex in cyst fluid)
Detection of Echinoccocus granulosus pathognomonic macroscopic morphology of cyst(s) in surgical specimens
Typical organ lesions detected by imaging techniques (e.g. computerised tomography, sonography, MRI) AND confirmed by a serological test
Echinococcus spp. specific serum antibodies by high-sensitivity serological test AND confirmed by a high specificity serological test
Detection of Echinococcus multilocularis or granulosus nucleic acid in a clinical specimen
Any person meeting the diagnostic criteria
Any person with at least one of the following four:
Diarrhoea
Abdominal pain
Bloating
Signs of malabsorption (e.g. steatorrhoea, weight loss)
At least one of the following two:
Demonstration of Giardia lamblia cysts or trophozoites in stool, duodenal fluid or small-bowel biopsy
Demonstration of Giardia lamblia antigen in stool
At least one of the following four epidemiological links:
Exposure to contaminated food/drinking water
Human to human transmission
Exposure to a common source
Environmental exposure
Any person meeting the clinical criteria and with an epidemiological link
Any person meeting the clinical and the laboratory criteria
Any person with at least one of the following eight:
Urethritis
Acute salpingitis
Pelvic inflammatory disease
Cervicitis
Epididymitis
Proctitis
Pharyngitis
Arthritis
OR
Any newborn child with conjunctivitis
At least one of the following four:
Isolation of Neisseria gonorrhoeae from a clinical specimen
Detection of Neisseria gonorrhoeae nucleic acid in a clinical specimen
Demonstration of Neisseria gonorrhoeae by a non-amplified nucleic acid probe test in a clinical specimen
Microscopic detection of intracellular gram negative diploccocci in a urethral male specimen
An epidemiological link by human to human transmission (sexual contact or vertical transmission)
Any person meeting the clinical criteria and with an epidemiological link
Any person meeting the laboratory criteria
Not relevant for surveillance purposes
At least one of the following two:
Isolation of Haemophilus influenzae from a normally sterile site
Detection of Haemophilus influenzae nucleic acid from a normally sterile site
Any person meeting the laboratory criteria
Any person with a discrete onset of symptoms (e.g. fatigue, abdominal pain, loss of appetite, intermittent nausea and vomiting)
AND
At least one of the following three:
Fever
Jaundice
Elevated serum aminotransferase levels
At least one of the following three:
Detection of hepatitis A virus nucleic acid in serum or stool
Hepatitis A virus specific antibody response
Detection of hepatitis A virus antigen in stool
At least one of the following four:
Human to human transmission
Exposure to a common source
Exposure to contaminated food/drinking water
Environmental exposure
Any person meeting the clinical criteria and with an epidemiological link
Any person meeting the clinical and the laboratory criteria
Not relevant for surveillance purposes
Positive results of at least one or more of the following tests or combination of tests:
IgM hepatitis B core antibody (anti-HBc IgM)
Hepatitis B surface antigen (HBsAg)
Hepatitis B e antigen (HBeAg)
Hepatitis B nucleic acid (HBV-DNA)
Not relevant for surveillance purposes
Any person meeting the laboratory criteria
Not relevant for surveillance purposes
At least one of the following three:
Detection of hepatitis C virus nucleic acid (HCV RNA)
Detection of hepatitis C virus core antigen (HCV-core)
Hepatitis C virus specific antibody (anti-HCV) response confirmed by a confirmatory (e.g. immunoblot) antibody test in persons older than 18 months without evidence of resolved infection)
Any person meeting the laboratory criteria
Any person with at least one of the following clinical forms:
Sudden onset of symptoms
AND
at least one of the following four systemic symptoms:
Fever or feverishness
Malaise
Headache
Myalgia
AND
At least one of the following three respiratory symptoms:
Cough
Sore throat
Shortness of breath
Sudden onset of symptoms
AND
At least one of the following four respiratory symptoms:
Cough
Sore throat
Shortness of breath
Coryza
AND
A clinician’s judgement that the illness is due to an infection
At least one the following four:
Isolation of influenza virus from a clinical specimen
Detection of influenza virus nucleic acid in a clinical specimen
Identification of influenza virus antigen by DFA test in a clinical specimen
Influenza specific antibody response
Sub typing of the influenza isolate should be performed, if possible
An epidemiological link by human to human transmission
Any person meeting the clinical criteria (ILI or ARI)
Any person meeting the clinical criteria (ILI or ARI) and with an epidemiological link
Any person meeting the clinical (ILI or ARI) and the laboratory criteria
Any person with one of the following three:
fever > 38 °C AND signs and symptoms of acute respiratory infection
pneumonia (severe respiratory illness)
death from an unexplained acute respiratory illness
At least one of the following tests:
RT-PCR
viral culture (requiring BSL 3 facilities)
four-fold rise in novel influenza virus A(H1N1) specific neutralising antibodies (implies the need for paired sera, from acute phase illness and then at convalescent stage 10-14 days later minimum)
At least one of the following three in the seven days before disease onset:
a person who was a close contact to a confirmed case of novel influenza A(H1N1) virus infection while the case was ill
a person who has travelled to an area where sustained human-to-human transmission of novel influenza A(H1N1) is documented
a person working in a laboratory where samples of the novel influenza A(H1N1) virus are tested
Any person meeting the clinical and epidemiological criteria
Any person meeting the clinical AND epidemiological criteria AND with a laboratory result showing positive influenza A infection of an unsubtypable type
Any person meeting the laboratory criteria for confirmation
Any person with pneumonia
Laboratory criteria for case confirmation
At least one of the following three:
Isolation of Legionella spp. from respiratory secretions or any normally sterile site
Detection of Legionella pneumophila antigen in urine
Significant rise in specific antibody level to Legionella pneumophila serogroup 1 in paired serum samples
Laboratory criteria for a probable case
At least one of the following four:
Detection of Legionella pneumophila antigen in respiratory secretions or lung tissue e.g. by DFA staining using monoclonal-antibody derived reagents
Detection of Legionella spp. nucleic acid in respiratory secretions, lung tissue or any normally sterile site
Significant rise in specific antibody level to Legionella pneumophila other than serogroup 1 or other Legionella spp. in paired serum samples
Single high level of specific antibody to Legionella pneumophila serogroup 1 in serum
Any person meeting the clinical criterion AND at least one laboratory criterion for a probable case
Any person meeting the clinical criterion AND at least one laboratory criterion for a confirmed case
Any person with
Fever
OR
At least two of the following eleven:
Chills
Headache
Myalgia
Conjunctival suffusion
Haemorrhages into skin and mucous membranes
Rash
Jaundice
Myocarditis
Meningitis
Renal impairment
Respiratory symptoms such as haemoptysis
At least one of the following four:
Isolation of Leptospira interrogans or any other pathogenic Leptospira spp. from a clinical specimen
Detection of Leptospira interrogans or any other pathogenic Leptospira spp. nucleic acid in a clinical specimen
Demonstration of Leptospira interrogans or any other pathogenic Leptospira spp. by immunofluorescence in a clinical specimen
Leptospira interrogans or any other pathogenic Leptospira spp. specific antibody response
At least one of the following three epidemiological links:
Animal to human transmission
Environmental exposure
Exposure to a common source
Any person meeting the clinical criteria and with an epidemiological link
Any person meeting the clinical and the laboratory criteria
Any person with at least one of the following three:
Listeriosis of newborns defined as
Stillbirth
OR
At least one of the following five in the first month of life:
Granulomatosis infantiseptica
Meningitis or meningoencephalitis
Septicaemia
Dyspnoea
Lesions on skin, mucosal membranes or conjunctivae
Listeriosis in pregnancy defined as at least one of the following three:
Abortion, miscarriage, stillbirth or premature birth
Fever
Influenza-like symptoms
Other form of listeriosis defined as at least one of the following four:
Fever
Meningitis or meningoencephalitis
Septicaemia
Localised infections such as arthritis, endocarditis, and abscesses
At least one of the following two:
Isolation of Listeria monocytogenes from a normally sterile site
Isolation of Listeria monocytogenes from a normally non-sterile site in a foetus, stillborn, newborn or the mother at or within 24 hours of birth
At least one of the following three epidemiological links:
Exposure to a common source
Human to human transmission (vertical transmission)
Exposure to contaminated food/drinking water
Incubation period 3-70 days, most often 21 days
Any person meeting the clinical criteria and with an epidemiological link
Any person meeting the laboratory criteria
OR
Any mother with a laboratory confirmed listeriosis infection in her foetus, stillborn or newborn
Any person with fever OR a history of fever
At least one of the following three:
Demonstration of malaria parasites by light microscopy in blood films
Detection of Plasmodium nucleic acid in blood
Detection of Plasmodium antigen
Differentiation of Plasmodium spp. should be performed if possible
Any person meeting the clinical and the laboratory criteria
Any person with fever
AND
Maculo-papular rash
AND at least one of the following three:
Cough
Coryza
Conjunctivitis
At least one of the following four:
Isolation of measles virus from a clinical specimen
Detection of measles virus nucleic acid in a clinical specimen
Measles virus specific antibody response characteristic for acute infection in serum or saliva
Detection of measles virus antigen by DFA in a clinical specimen using measles specific monoclonal antibodies
Laboratory results need to be interpreted according to the vaccination status. If recently vaccinated, investigate for wild virus
An epidemiological link by human to human transmission
Any person meeting the clinical criteria
Any person meeting the clinical criteria and with an epidemiological link
Any person not recently vaccinated and meeting the clinical and the laboratory criteria
Any person with at least one of the following symptoms:
Meningeal signs
Haemorrhagic rash
Septic shock
Septic arthritis
At least one of the following four:
Isolation of Neisseria meningitidis from a normally sterile site, or from purpuric skin lesions
Detection of Neisseria meningitidis nucleic acid from a normally sterile site, or from purpuric skin lesions
Detection of Neisseria meningitidis antigen in CSF
Detection of gram negative stained diplococcus in CSF
An epidemiological link by human to human transmission
Any person meeting the clinical criteria
Any person meeting the clinical criteria and with an epidemiological link
Any person meeting the laboratory criteria
Any person with
Fever
AND
At least one of the following three:
Sudden onset of unilateral or bilateral tender swelling of the parotid or other salivary glands without other apparent cause
Orchitis
Meningitis
At least one of the following three:
Isolation of mumps virus from a clinical specimen
Detection of mumps virus nucleic acid
Mumps virus specific antibody response characteristic for acute infection in serum or Saliva
Laboratory results need to be interpreted according to the vaccination status
An epidemiological link by human to human transmission
Any person meeting the clinical criteria
Any person meeting the clinical criteria and with an epidemiological link
Any person not recently vaccinated and meeting the laboratory criteria
In case of recent vaccination: any person with detection of wild-type mumps virus strain
Any person with a cough lasting at least two weeks
AND at least one of the following three:
Paroxysms of coughing
Inspiratory ‘whooping’
Post-tussive vomiting
OR
Any person diagnosed as pertussis by a physician
OR
Apnoeic episodes in infants
At least one of the following three:
Isolation of Bordetella pertussis from a clinical specimen
Detection of Bordetella pertussis nucleic acid in a clinical specimen
Bordetella pertussis specific antibody response
An epidemiological link by human to human transmission
Any person meeting the clinical criteria
Any person meeting the clinical criteria and with an epidemiological link
Any person meeting the clinical and the laboratory criteria
Any person with at least one of the following clinical forms:
Fever
AND
Sudden onset of painful lymphadenitis
Fever
Fever
AND
At least one of the following three:
Cough
Chest pain
Haemoptysis
At least one of the following three:
Isolation of Yersinia pestis from a clinical specimen
Detection of Yersinia pestis nucleic acid from a clinical specimen (F1 antigen)
Yersinia pestis anti-F1 antigen specific antibody response
At least one of the following four epidemiological links:
Human to human transmission
Animal to human transmission
Laboratory exposure (where there is a potential exposure to plague)
Exposure to a common source
Any person meeting the clinical criteria and with an epidemiological link
Any person meeting the laboratory criteria
Not relevant for surveillance purposes
At least one of the following three:
Isolation of Streptococcus pneumoniae from a normally sterile site
Detection of Streptococcus pneumoniae nucleic acid from a normally sterile site
Detection of Streptococcus pneumoniae antigen from a normally sterile site
Any person meeting the laboratory criteria
Any person < 15 years of age with Acute flaccid paralysis (AFP)
OR
Any person in whom polio is suspected by a physician
At least one of the following three:
Isolation of a polio virus and intratypic differentiation — Wild polio virus (WPV)
Vaccine derived poliovirus (VDPV) (for the VDPV at least 85 % similarity with vaccine virus in the nucleotide sequences in the VP1 section)
Sabin-like poliovirus: intratypic differentiation performed by a WHO-accredited polio laboratory (for the VDPV a > 1 % up to 15 % VP1 sequence difference compared with vaccine virus of the same serotype)
At least one of the following two epidemiological links:
Human to human transmission
An history of travel to a polio-endemic area or an area with suspected or confirmed circulation of poliovirus
Any person meeting the clinical criteria
Any person meeting the clinical criteria and with an epidemiological link
Any person meeting the clinical and the laboratory criteria
Any person with at least one of the following three:
Fever
Pneumonia
Hepatitis
At least one of the following three:
Isolation of Coxiella burnetii from a clinical specimen
Detection of Coxiella burnetii nucleic acid in a clinical specimen
Coxiella burnetii specific antibody response (IgG or IgM phase II)
At least one of the following two epidemiological links:
Exposure to a common source
Animal to human transmission
Any person meeting the clinical criteria and with an epidemiological link
Any person meeting the clinical and the laboratory criteria
Any person with an acute encephalomyelitis
AND
At least two of the following seven:
Sensory changes referred to the site of a preceding animal bite
Paresis or paralysis
Spasms of swallowing muscles
Hydrophobia
Delirium
Convulsions
Anxiety
At least one of the following four:
Isolation of Lyssa virus from a clinical specimen
Detection of Lyssa virus nucleic acid in a clinical specimen (e.g. saliva or brain tissue)
Detection of viral antigens by a DFA in a clinical specimen
Lyssa virus specific antibody response by virus neutralisation assay in serum or CSF
Laboratory results need to be interpreted according to the vaccination or immunisation status
At least one of the following three epidemiological links:
Animal to human transmission (animal with suspected or confirmed infection)
Exposure to a common source (same animal)
Human to human transmission (e.g. transplantation of organs)
Any person meeting the clinical criteria
Any person meeting the clinical criteria and with an epidemiological link
Any person meeting the clinical and the laboratory criteria
Any person with sudden onset of generalised maculo-papular rash
AND
At least one of the following five:
Cervical adenopathy
Sub-occipital adenopathy
Post-auricular adenopathy
Arthralgia
Arthritis
Laboratory criteria for case confirmation
At least one of the following three:
Isolation of rubella virus from a clinical specimen
Detection of rubella virus nucleic acid in a clinical specimen
Rubella virus specific antibody response (IgG) in serum or saliva
Laboratory criteria for probable case
Rubella virus specific antibody response (IgM(10))
Laboratory results need to be interpreted according to the vaccination status
An epidemiological link by human to human transmission
Any person meeting the clinical criteria
Any person meeting the clinical criteria and with at least one of the following two:
An epidemiological link
Meeting the laboratory criteria for a probable case
Any person not recently vaccinated and meeting the laboratory criteria for case confirmation
In case of recent vaccination, a person with detection of wild-type rubella virus strain
No clinical criteria can be defined for CRI
Any infant < 1 year of age or any stillborn with:
At least two of the conditions listed in (A)
OR
One in category (A) and one in category (B)
Cataract(s)
Congenital glaucoma
Congenital heart disease
Loss of hearing
Pigmentary retinopathy
Purpura
Splenomegaly
Microcephaly
Developmental delay
Meningo-encephalitis
Radiolucent bone disease
Jaundice that begins within 24 hours after birth
At least one of the following four:
Isolation of rubella virus from a clinical specimen
Detection of Rubella virus nucleic acid
Rubella virus specific antibody response (IgM)
Persistence of rubella IgG between 6 and 12 months of age (at least two samples with similar concentration of rubella IgG)
Laboratory results need to be interpreted according to the vaccination status
Any infant or any stillborn born to a woman with a laboratory confirmed rubella infection during pregnancy by human to human transmission (vertical transmission)
Any stillborn or infant either not tested OR with negative laboratory results with at least one of the following two:
An epidemiological link AND at least one of the conditions listed in the category ‘A’ CRS clinical criteria
Meeting the clinical criteria for CRS
Any stillborn meeting the laboratory criteria
OR
Any infant meeting the laboratory criteria AND at least one of the following two:
An epidemiological link
At least one of the conditions listed in the category ‘A’ CRS clinical criteria
Any person with at least one of the following four:
Diarrhoea
Fever
Abdominal pain
Vomiting
Isolation of Salmonella (other than Salmonella typhi and Salmonella paratyphi) from stool, urine, body site (e.g. infected wound) or any normally sterile body fluids and tissues (e.g. blood, CSF, bone, synovial fluid, etc.)
At least one of the following five epidemiological links:
Human to human transmission
Exposure to a common source
Animal to human transmission
Exposure to contaminated food/drinking water
Environmental exposure
Any person meeting the clinical criteria and with an epidemiological link
Any person meeting the clinical and the laboratory criteria
Any person with fever or a history of fever
AND
At least one of the following three:
Cough
Difficulty in breathing
Shortness of breath
AND
At least one of the following four:
Radiographic evidence of pneumonia
Radiographic evidence of acute respiratory distress syndrome
Autopsy findings of pneumonia
Autopsy findings of acute respiratory distress syndrome
AND
No alternative diagnosis which can fully explain the illness
Laboratory criteria for case confirmation
At least one of the following three:
Isolation of virus in cell culture from any clinical specimen and identification of SARS-CoV using method such as RT-PCR
Detection SARS-CoV nucleic acid in at least one of the following three:
At least two different clinical specimens (e.g. nasopharyngeal swab and stool)
The same clinical specimen collected on two or more occasions during the course of the illness (e.g. sequential nasopharyngeal aspirates)
Two different assays or repeat RT-PCR using a new RNA extract from the original clinical sample on each occasion of testing
SARS-CoV specific antibody response by one of the following two:
Seroconversion by ELISA or IFA in acute and convalescent phase serum tested in parallel
Four-fold or greater rise in antibody titre between acute and convalescent phase sera tested in parallel
Laboratory criteria for a probable case
At least one of the following two:
A single positive antibody test for SARS-CoV
A positive PCR result for SARS-CoV on a single clinical specimen and assay
At least one of the following three:
Any person with at least one of the following three:
Employed in an occupation associated with an increased risk of SARS-CoV exposure (e.g. staff in a laboratory working with live SARS-CoV/SARS-CoV-like viruses or storing clinical specimens infected with SARS-CoV; persons with exposure to wildlife or other animals considered a reservoir of SARS-CoV, their excretions or secretions, etc.)
Close contact(11) of one or more persons with confirmed SARS or under investigation for SARS
History of travel to, or residence in, an area experiencing an outbreak of SARS
Two or more health-care workers(12) with clinical evidence of SARS in the same health-care unit and with onset of illness in the same 10-day period
Three or more persons (health-care workers and/or patients and/or visitors) with clinical evidence of SARS with onset of illness in the same 10-day period and epidemiologically linked to a healthcare facility
Also applies during an outbreak in a non-affected country or area
Any person meeting the clinical criteria and with an epidemiological link
Any person meeting the clinical criteria AND with an epidemiological link AND meeting the laboratory criteria for a probable case
Any person meeting the clinical and the laboratory criteria for case confirmation where the testing has been performed at a national reference laboratory
Any person meeting the clinical and the laboratory criteria for case confirmation where the testing has been performed at a WHO SARS verification and reference laboratory
Applies during an outbreak in a country/area where at least one person has been laboratory confirmed by a WHO SARS verification and reference laboratory
Any person meeting the clinical criteria
Any person meeting the clinical criteria and with an epidemiological link to a nationally confirmed or a confirmed case
Any person meeting the clinical and the laboratory criteria for case confirmation where the testing has been performed at a national reference laboratory
One of the following three:
Any person meeting the clinical and the laboratory criteria for case confirmation where the testing has been performed at a WHO SARS verification and reference laboratory
Any nationally confirmed case with an epidemiological link to a chain of transmission where at least one case has been independently verified by a WHO SARS Reference and Verification Laboratory
Any person meeting the clinical criteria and with laboratory criteria for probable case with an epidemiological link to a chain of transmission where at least one case has been independently verified by a WHO SARS Reference and Verification Laboratory
Any person with at least one of the following two:
Diarrhoea
Abdominal pain
Any person with acute renal failure and at least one of the following two:
Microangiopatic haemolytic anaemia
Thrombocytopenia
At least one of the following four:
Isolation of an Escherichia coli strain that produces Shigatoxin (Stx) or harbours stx1 or stx2 gene(s)
Isolation of non-sorbitol-fermenting (NSF) Escherichia coli O157 (without Stx or stx gene testing)
Direct detection of stx1 or stx2 gene(s) nucleic acid (without strain isolation)
Direct detection of free Stx in faeces (without strain isolation)
Only for HUS the following can be used as laboratory criterion to confirm STEC/VTEC:
Escherichia coli serogroup-specific (LPS) antibody response
Isolation of an STEC/VTEC strain and additional characterisation by serotype, phage type, eae genes, and subtypes of stx1/stx2 should be performed if possible
At least one of the following five epidemiological links:
Human to human transmission
Exposure to a common source
Animal to human transmission
Exposure to contaminated food/drinking water
Environmental exposure
Any person meeting the clinical criteria for HUS
Any person meeting the clinical criteria and with an epidemiological link
Any person meeting the clinical and the laboratory criteria
Any person with at least one of the following four:
Diarrhoea
Fever
Vomiting
Abdominal pain
Isolation of Shigella spp. from a clinical specimen
At least one of the following five epidemiological links:
Human to human transmission
Exposure to a common source
Animal to human transmission
Exposure to contaminated food/drinking water
Environmental exposure
Any person meeting the clinical criteria and with an epidemiological link
Any person meeting the clinical and the laboratory criteria
Any person with at least one of the following two:
Fever
AND
Vesicles or firm pustules rash at the same stage of development with a centrifugal distribution
Atypical presentations defined as at least one of the following four:
Haemorrhagic lesions
Flat velvety lesions not progressing to vesicles
Variola sine eruptione
Milder type
Laboratory criteria for case confirmation
At least one of the following two laboratory tests:
Isolation of smallpox (Variola virus) from a clinical specimen followed by sequencing (designated P4 laboratories only)
Detection of Variola virus nucleic acid in a clinical specimen followed by sequencing
Laboratory results need to be interpreted according to the vaccination status
Laboratory criteria for a probable case
Identification of orthopox virus particles by EM
At least one of the following two epidemiological links:
Human to human transmission
Laboratory exposure (where there is a potential exposure to Variola virus)
Any person meeting the clinical criteria
Any person meeting the clinical criteria and with at least one of the following two:
An epidemiological link to a confirmed human case by human to human transmission
Meeting the laboratory criteria for a probable case
Any person meeting the laboratory criteria for case confirmation
During an outbreak: any person meeting the clinical criteria and with an epidemiological link
Primary syphilis
Any person with one or several (usually painless) chancres in the genital, perineal, anal area or mouth or pharyngeal mucosa or elsewhere extragenitally
Secondary syphilis
Any person with at least one of the following five:
Diffuse maculo-papular rash often involving palms and soles
Generalised lymphadenopathy
Condyloma lata
Enanthema
Allopetia diffusa
Early latent syphilis (< 1 year)
A history of symptoms compatible with those of the earlier stages of syphilis within the previous 12 months
Late latent syphilis (> 1 year)
Any person meeting laboratory criteria (specific serological tests)
At least one of the following four laboratory tests:
Demonstration of Treponema pallidum in lesion exudates or tissues by dark-field microscopic examination
Demonstration of Treponema pallidum in lesion exudates or tissues by DFA test
Demonstration of Treponema in lesion exudates or tissues by PCR
Detection of Treponema pallidum antibodies by screening test (TPHA, TPPA or EIA) AND additionally detection of Tp-IgM antibodies (by IgM-ELISA, IgM immunoblot or 19S-IgM-FTA-abs) — confirmed by a second IgM assay
Primary/secondary syphilis
An epidemiological link by human to human (sexual contact)
Early latent syphilis (< 1 year)
An epidemiological link by human to human (sexual contact) within the 12 previous months
Any person meeting the clinical criteria and with an epidemiological link
Any person meeting the laboratory criteria for case confirmation
Any infant < 2 years of age with at least one of the following 10:
Hepatospenomegaly
Mucocutaneous lesions
Condyloma lata
Persistent rhinitis
Jaundice
Pseudoparalysis (due to periostitis and osteochondritis)
Central nervous involvement
Anaemia
Nephrotic syndrome
Malnutrition
Laboratory criteria for case confirmation
At least one of the following three:
Demonstration of Treponema pallidum by dark field microscopy in the umbilical cord, the placenta, a nasal discharge or skin lesion material
Demonstration of Treponema pallidum by DFA-TP in the umbilical cord, the placenta, a nasal discharge or skin lesion material
Detection of Treponema pallidum — specific IgM (FTA-abs, EIA)
AND a reactive non-treponemal test (VDRL, RPR) in the child’s serum
Laboratory criteria for a probable case
At least one of the following three:
Reactive VDRL-CSF test result
Reactive non-treponemal and treponemal serologic tests in the mother’s serum
Infant’s non-treponemal antibody titre is four-fold or greater than the antibody titre in the mother’s serum
Any infant with an epidemiological link by human to human transmission (vertical transmission)
Any infant or child meeting the clinical criteria and with at least one of the following two:
An epidemiological link
Meeting the laboratory criteria for a probable case
Any infant meeting the laboratory criteria for case confirmation
Any person with at least two of the following three:
Painful muscular contractions primarily of the masseter and neck muscles leading to facial spasms known as trismus and ‘risus sardonicus’
Painful muscular contractions of trunk muscles
Generalised spasms, frequently position of opisthotonus
At least one of the following two:
Isolation of Clostridium tetani from an infection site
Detection of tetanus toxin in a serum sample
Any person meeting the clinical criteria
Any person meeting the clinical and the laboratory criteria
Any person with symptoms of inflammation of the CNS (e.g. meningitis, meningo-encephalitis, encephalomyelitis, encephaloradiculitis)
Laboratory criteria for case confirmation:
At least one of the following five:
TBE specific IgM AND IgG antibodies in blood
TBE specific IgM antibodies in CSF
Sero-conversion or four-fold increase of TBE-specific antibodies in paired serum samples
Detection of TBE viral nucleic acid in a clinical specimen,
Isolation of TBE virus from clinical specimen
Laboratory criteria for a probable case:
Detection of TBE-specific IgM-antibodies in a unique serum sample
Exposure to a common source (unpasteurised dairy products)
Any person meeting the clinical criteria and the laboratory criteria for a probable case,
OR
Any person meeting the clinical criteria and with an epidemiological link
Any person meeting the clinical and laboratory criteria for case confirmation
Not relevant for surveillance purposes
At least one of the following four:
Demonstration of Toxoplasma gondii in body tissues or fluids
Detection of Toxoplasma gondii nucleic acid in a clinical specimen
Toxoplasma gondii specific antibody response (IgM, IgG, IgA) in a newborn
Persistently stable IgG Toxoplasma gondii titres in an infant (< 12 months of age)
Any infant meeting the laboratory criteria
Any person with at least three of the following six:
Fever
Muscle soreness and pain
Diarrhoea
Facial oedema
Eosinophilia
Subconjunctival, subungual and retinal haemorrhages
At least one of the following two:
Demonstration of Trichinella larvae in tissue obtained by muscle biopsy
Trichinella specific antibody response (IFA test, ELISA or Western Blot)
At least one of the following two epidemiological links:
Exposure to contaminated food (meat)
Exposure to a common source
Any person meeting the clinical criteria and with an epidemiological link
Any person meeting the clinical criteria and the laboratory criteria
Any person with the following two:
Signs, symptoms and/or radiological findings consistent with active tuberculosis in any site
AND
A clinician’s decision to treat the person with a full course of anti-tuberculosis therapy
OR
A case discovered post-mortem with pathological findings consistent with active tuberculosis that would have indicated anti-tuberculosis antibiotic treatment had the patient been diagnosed before dying
Laboratory criteria for case confirmation
At least one of the following two:
Isolation of Mycobacterium tuberculosis complex (excluding Mycobacterium bovis-BCG) from a clinical specimen
Detection of Mycobacterium tuberculosis complex nucleic acid in a clinical specimen AND positive microscopy for acid-fast bacilli or equivalent fluorescent staining bacilli on light microscopy
Laboratory criteria for a probable case
At least one of the following three:
Microscopy for acid-fast bacilli or equivalent fluorescent staining bacilli on light microscopy
Detection of Mycobacterium tuberculosis complex nucleic acid in a clinical specimen
Histological appearance of granulomata
Any person meeting the clinical criteria
Any person meeting the clinical criteria and the laboratory criteria for a probable case
Any person meeting the clinical and the laboratory criteria for case confirmation
Any person with at least one of the following clinical forms:
Ulceroglandular tularaemia
Cutaneous ulcer
AND
Regional lymphadenopathy
Glandular tularaemia
Enlarged and painful lymph nodes without apparent ulcer
Oculoglandular tularaemia
Conjunctivitis
AND
Regional lymphadenopathy
Oropharyngeal tularaemia
Cervical lymphadenopathy
AND at least one of the following three:
Stomatitis
Pharyngitis
Tonsillitis
Intestinal tularaemia
At least one of the following three:
Abdominal pain
Vomiting
Diarrhoea
Pneumonic tularaemia
Pneumonia
Typhoidal tularaemia
At least one of the following two:
Fever without early localising signs and symptoms
Septicaemia
At least one of the following three:
Isolation of Francisella tularensis from a clinical specimen
Detection of Francisella tularensis nucleic acid in a clinical specimen
Francisella tularensis specific antibody response
At least one of the following three epidemiological links:
Exposure to a common source
Animal to human transmission
Exposure to contaminated food/drinking water
Any person meeting the clinical criteria and with an epidemiological link
Any person meeting the clinical and the laboratory criteria
Any person with at least one of the following two:
Onset of sustained fever
At least two of the following four:
Headache
Relative bradycardia
Non-productive cough
Diarrhoea, constipation, malaise or abdominal pain
Paratyphoid fever has the same symptoms as typhoid fever, however usually a milder course
Isolation of Salmonella typhi or paratyphi from a clinical specimen
At least one of the following three epidemiological links:
Exposure to a common source
Human to human transmission
Exposure to contaminated food/drinking water
Any person meeting the clinical criteria and with an epidemiological link
Any person meeting the clinical and the laboratory criteria
Any person with at least one of the following two:
Fever
Haemorrhagic manifestations in various forms that may lead to multi-organ failure
At least one of the following two:
Isolation of specific virus from a clinical specimen
Detection of specific virus nucleic acid in a clinical specimen and genotyping
At least one of the following:
Travel in the last 21 days to a region where VHF cases are known or believed to have occurred
Exposure within the last 21 days to a probable or confirmed case of a VHF whose onset of illness was within the last six months
Any person meeting the clinical criteria and with an epidemiological link
Any person meeting the clinical and the laboratory criteria
Any person with Fever
OR
At least one of the following two:
Encephalitis
Meningitis
Laboratory test for case confirmation
At least one of the following four:
Isolation of WNV from blood or CSF
Detection of WNV nucleic acid in blood or CSF
WNV specific antibody response (IgM) in CSF
WNV IgM high titre AND detection of WNV IgG, AND confirmation by neutralisation
Laboratory test for a probable case
WNV specific antibody response in serum
Laboratory results need to be interpreted according to flavivirus vaccination status
At least one of the following two epidemiological links:
Animal to human transmission (residing, having visited or having been exposed to mosquito bites in an area where WNV is endemic in horses or birds)
Human to human transmission (vertical transmission, blood transfusion, transplants)
Any person meeting the clinical criteria AND with at least one of the following two:
an epidemiological link
a laboratory test for a probable case
Any person meeting the laboratory criteria for case confirmation
Any person with Fever
AND
At least one of the following two:
Jaundice
Generalised haemorrhage
At least one of the following five:
Isolation of yellow fever virus from a clinical specimen
Detection of yellow fever virus nucleic acid
Detection of yellow fever antigen
Yellow fever specific antibody response
Demonstration of typical lesions in post mortem liver histopathology
Laboratory results need to be interpreted according to flavivirus vaccination status
Travel in the last 1 week to a region where yellow fever cases are known or believed to have occurred
Any person meeting the clinical criteria and with an epidemiological link
Any person not recently vaccinated meeting the clinical and the laboratory criteria
In case of recent vaccination, a person with detection of wild-type yellow fever virus strain
Any person with at least one of the following five:
Fever
Diarrhoea
Vomiting
Abdominal pain (pseudoappendicitis)
Tenesmus
Isolation of human pathogenic Yersinia enterocolitica or Yersinia pseudotuberculosis from a clinical specimen
At least one of the following four epidemiological links:
Human to human transmission
Exposure to a common source
Animal to human transmission
Exposure to contaminated food
Any person meeting the clinical criteria and with an epidemiological link
Any person meeting the clinical and the laboratory criteria
See World Organisation for Animal Health — OIE — and European Commission (SANCO) Animal Disease Notification System (ADNS), available at: http://www.oie.int/eng/en_index.htm, and http://ec.europa.eu/food/animal/diseases/adns/index_en.htm#)
This does not include seemingly well birds that have been killed, for example by hunting.
Depression, anxiety, apathy, withdrawal, delusions.
This includes both frank pain and/or dysaesthesia.
The typical appearance of the EEG in sporadic CJD consists of generalised periodic complexes at approximately one per second. These may occasionally be seen in the late stages of vCJD.
See footnote 5.
Tonsil biopsy is not recommended routinely nor in cases with EEG appearances typical of sporadic CJD, but may be useful in suspect cases in which the clinical features are compatible with vCJD and MRI does not show pulvinar high signal.
See footnote 5.
See footnote 5.
When rubella in pregnancy is suspected, further confirmation of a positive rubella IgM results is required (e.g. a rubella specific IgG avidity test showing a low avidity). In certain situations, such as confirmed rubella outbreaks detection of rubella virus IgM can be considered confirmatory in non-pregnant cases.
A close contact is a person who has cared for, lived with, or having had direct contact with the respiratory secretions, body fluids and/or excretions (e.g. faeces) of cases of SARS.
In this context the term ‘health-care worker’ includes all hospital staff. The definition of the health care unit in which the cluster occurs will depend on the local situation. Unit size may range from an entire health care facility if small, to a single department or ward of a large tertiary hospital.
Serological results should be interpreted according to the vaccination status and previous exposure to other flaviviral infections. Confirmed cases in such situations should be validated by serum neutralisation assay or other equivalent assays.
The Whole Decision you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
The Schedules you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As adopted by EU): The original version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
This timeline shows the different versions taken from EUR-Lex before exit day and during the implementation period as well as any subsequent versions created after the implementation period as a result of changes made by UK legislation.
The dates for the EU versions are taken from the document dates on EUR-Lex and may not always coincide with when the changes came into force for the document.
For any versions created after the implementation period as a result of changes made by UK legislation the date will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. For further information see our guide to revised legislation on Understanding Legislation.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: